OncoMatch/Clinical Trials/NCT06946225
ACTengine® IMA203 Combined With mRNA-4203
Is NCT06946225 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IMA203 and mRNA-4203 for cutaneous melanoma.
Treatment: IMA203 · mRNA-4203 — This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Sarcoma
Biomarker criteria
Required: HLA-A A*02:01 positive
HLA-A*02:01 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor
Must have received: systemic therapy
SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy.
Cannot have received: allogenic stem cell transplantation
Prior allogenic stem cell transplantation
Cannot have received: solid organ transplantation
Prior ... solid organ transplantation
Lab requirements
Liver function
Adequate selected organ function per protocol
Adequate selected organ function per protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Francisco · San Francisco, California
- Dana Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify